Doxycycline reduces osteopenia in female rats

Area of Science:

• Pharmacology
• Bone Biology
• Endocrinology

Background:

• Doxycycline, a tetracycline antibiotic, also possesses anti-inflammatory properties and inhibits Matrix Metalloproteinases (MMPs).
• Its action as a calcium chelator suggests potential interference with bone remodeling processes.
• Osteopenia, a condition characterized by reduced bone mass, is a significant concern, particularly post-ovariectomy.

Purpose of the Study:

• To investigate the efficacy of doxycycline in controlling osteopenia.
• To evaluate the effects of different doxycycline dosages (10 and 30 mg/kg/day) on bone health in a rat model.
• To assess doxycycline's impact on bone densitometry, histology, and biochemical markers in both control and ovariectomized rats.

Main Methods:

• Sixty-three Wistar rats were divided into nine groups, including control, ovariectomized (OVX), and sedentary (Se) groups, treated with varying doxycycline doses or water.
• Bone densitometry, histological analysis of femoral bones, and biochemical quantification (calcium, magnesium) of tibial and serum samples were performed.
• Statistical analysis utilized a multivariate general linear model (ANOVA) with Bonferroni adjustment and non-parametric tests for TRAP analysis (p < 0.05).

Main Results:

• Doxycycline treatment (10 and 30 mg/kg/day) significantly improved bone mineral content (BMC), bone mineral density (BMD), and cancellous bone in OVX rats.
• Significant improvements were observed in BMC, magnesium, and cancellous bone in sedentary rats treated with doxycycline compared to controls.
• Doxycycline exhibited a deleterious effect on bone parameters in the control groups, while showing positive effects on bone organization in OVX rats.

Conclusions:

• Doxycycline demonstrates a beneficial role in mitigating ovariectomy-induced osteopenia in rats, enhancing bone organization and density.
• The drug's effects are dose-dependent and context-specific, showing positive outcomes in osteopenic models but adverse effects in healthy controls.
• Further research is warranted to elucidate the precise mechanisms and optimize doxycycline's therapeutic application in bone-related disorders.